NEW YORK — PMI Biopharma Solutions has partnered Nashville Biosciences to offer drug discovery and development services, the companies said on Friday.
Under the terms of the deal, the companies will offer Nashville Biosciences' genomic data and in silico technologies with PMI's lab and research services as a combined package for drug target identification and validation.
A subsidiary of Vanderbilt University Medical Center, Nashville Biosciences uses Vanderbilt's BioVU bank of longitudinal medical records and DNA samples to guide customers' R&D programs.
Additional terms of the deal were not disclosed.
"With both organizations located in Nashville, [Tennessee], it was an easy decision to pair our capabilities to better serve our clients," PMI CEO David Sunseri said in a statement. "This alliance will allow clients a smooth transition from in silico to in vitro studies."